Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

In comments submitted earlier this week, APC took issue with provisions of proposed new compounding regulations from the California Board of Pharmacy.

“We have serious concerns about the Board’s proposed regulations and the ongoing failure of the Board to root its regulation and enforcement of compounding in applicable law and science,” the letter states.

In addition to a cover letter enunciating five broad concerns about the Board’s proposal and its oversight of compounding in general, APC submitted detailed comments on specific provisions of the proposal. 

During the board’s public hearing on June 18, 2024, APC’s Tenille Davis will present the association’s concerns. Members and licensees in the state of California are urged to register to attend either virtually or in person. Details here.